Fusion QbD® – Integrated QbD Robustness



S-Matrix Corporation 1594 Myrtle Avenue Eureka, CA 95501 USA

Phone: 707-441-0404 URL: www.smatrix.com

Fusion QbD - Leading the Vision!

<u>2008 – Development of Integrated Robustness</u>

S-Matrix recognized very early the limitations and problems associated with the traditional approach to method validation robustness experimentation, and its inherent likelihood of *false negative* outcomes – characterizing a method as robust when it is not.

In response to this problem, S-Matrix integrated QbD robustness modeling and metrics into Fusion QbD according to rigorous statistical principles and industry best practices. This was done in cooperation with several leading international pharmaceutical company customers!



Fusion QbD – Leading the Vision!

2009: S-Matrix Presentation to the FDA

In 2009 S-Matrix made a major presentation to the FDA demonstrating its integration of QbD robustness modeling and metrics into Fusion QbD.

This presentation was extremely well received!



Fusion QbD – Leading the Vision!

2012+ - FDA Public Presentations

In 2012 the FDA began making public presentations about QbD robustness in analytical method and process development consistent with the robustness methodology and metrics integrated into Fusion QbD.

See the following slides...



Monte Carlo Robustness Simulation

"Statistical treatments (e.g., Monte Carlo simulations) can help evaluate the effects of uncertainty."

Points to Consider for Design Space – A Regulatory Perspective, Elaine Morefield, Ph.D., 2012 Annual Meeting, AAPS.

Statistical Robustness Metrics

The FDA has stated that accepted process capability indexes such as C_p , C_{pk} , C_{pm} , and C_{pkm} are also part of the QbD toolset.

US FDA, Quality by Design: Objectives, Benefits, and Challenges, Lawrence X. Yu, Ph.D., 2012 Annual Meeting, AAPS.





www.fda.gov

Method Operable Design Region

- Analytical method design space
 - Typically Design of Experiments is used to find ranges for instrument operating parameters and understand sources of variation.
 - Method performance criteria are response factors.
 - Can be conducted together with method validation.
- Considerations for implementing MODR
 - Availability of adequate data to support proposed MODR
 - Assess validation criteria across MODR
 - Confirm system suitability throughout MODR

4

John F. Kauffman, Ph.D. and Daniel J. Mans, Ph.D., "Experimental Design and Modeling to Improve HPLC Method Performance for Small Molecules", FDA Division of Pharmaceutical Analysis, CASSSCMC Strategy Forum Europe, 2015



System Suitability – Method Variation – Normal Distribution Bell Curve

System Suitability normally has two requirements:


- 1. Average Performance (\overline{X})
- 2. Repeatability (% RSD):

% RSD =
$$[(1.0\sigma / \overline{X})*100\%]$$

±3.0σ Width =
Overall Repeatability

Repeatability is a Robustness


Specification





C_{pk} – One-sided Specification Limit

Example: API Resolution



Specification Limit Delta (± Distance of Mean Response to Edge of Failure)

Performance Variation Bell Curve:

The numerical distance from the mean performance result to the specification limit.


$$C_{pk}$$
 – Goal is ≥ 1.33

Meaning – point of failure is 4σ away from \overline{X}




C_{pm} – Target with Two-sided Symmetrical Specification Limits

API Tailing Example:






Fusion QbD – Integrated Monte Carlo Robustness




Method Robustness versus Mean (\overline{X}) Performance

Do all methods within the Preliminary Design Space meet Robustness Requirements?







Monte Carlo Simulation – Simulate Many Injections






Fusion QbD – Establishes True Robust Design Space











Zoom in and Format Chromatogram View





Move Pointer and See how Chromatogram Changes





Move Pointer and See how Chromatogram Changes



Fusion QbD - Regulatory Guidance Aligned Reporting

ICH Q8(R2) - Page 22

C. Presentations of Design Space

Example 1: Response graphs for dissolution are depicted as a surface plot (Figure 1a) and a contour plot (Figure 1b). Parameters 1 and 2 are factors of a granulation operation that affect the dissolution rate of a tablet (e.g., excipient attribute, water amount, granule size.)





Figure 1a: Response surface plot of dissolution as a function of two parameters of a granulation operation. Dissolution above 80% is desired.

Figure 1b: Contour plot of dissolution from example 1a.







Figure 1c: Design space for granulation parameters, defined by a nonlinear combination of their ranges, that delivers satisfactory dissolution (i.e., >80%).


Figure 1d: Design space for granulation parameters, defined by a linear combination of their ranges, that delivers satisfactory dissolution (i.e., >80%).


Fusion QbD





Fusion QbD - Regulatory Guidance Aligned Reporting







Fusion QbD – the World is Catching Up!

3. Process Capability

Process capability refers to the performance of the process when it is operating under statistical control. Two capability indices are usually computed: C_p and C_{pk} in a similar way as was described with P_p and P_{pk} . However, C_p measures the **potential** capability in the process, if the process was centred, while C_{pk} measures the actual capability in a process which is off-centre or biased. If a process is centred, then $C_p = C_{pk}$.

$$C_{pk} = \min\left[\frac{U - \overline{X}}{3S_w}, \frac{\overline{X} - L}{3S_w}\right]$$
 (1.5)

The critical thing to note is that whilst the formulae for P_{pk} and C_{pk} look very similar, the standard deviation used to calculate the reference interval for C_{pk} is not S_t but S_w .

 S_w is the within batch standard deviation (called the within sub group standard deviation in ISO) not the overall process standard deviation. It is usually estimated from a Shewhart mean and range control chart using the formula

Page 78 of 80

European Compliance Agency, Analytical Quality Control Group, July 2018, Final_r1

